The role of fluorine- 18-fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma

Radiology and Oncology

Volumn 47, Issue 2, 2013, Pages 97-102

  Quartuccio, Natale ^a   Treglia, Giorgio ^b   Salsano, Marco ^c   Mattoli, Maria Vittoria ^d   Muoio, Barbara ^e   Piccardo, Arnoldo ^f   Lopci, Egesta ^g   Cistaro, Angelina ^h  

^a UNIVERSITY OF MESSINA   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c Istituto di Radiologia di Universita Cattolica del Sacro Cuore di Roma   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f Nuclear Medicine Unit GalUera Hospital   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h Positron Emission Tomography Centre IRMET SpA   (Italy)

Author keywords

8f fluorodeoxyglucose; Bone sarcoma; Osteosarcoma; Pet ct; Positron emission tomography

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; SUCCIMER TC 99M;

BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; GLUCOSE METABOLISM; HUMAN; INTERMETHOD COMPARISON; LUNG METASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; SOFT TISSUE SARCOMA; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SYSTEMATIC REVIEW; TREATMENT PLANNING;

EID: 84884999145     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/raon-2013-0017     Document Type: Review

References (31)

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115:1531-43.
2. Ritter I, Bielack SS. Osteosarcoma. Ann Oncol 2010; 21:320-5.
3. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341:342-52.
4. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-90. (Pubitemid 34111386)
5. Bielack S, Jurgens H, Jundt G, Kevric M, Kuhne T, Reichardt P, et al. Osteosarcoma: the COSS experience. Cancer Treat Res 2009; 152:289-308.
6. Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008; 98:415-20.
7. Bielack SS, Carrie D, Hardes i, Schuck A, Paulussen M. Bone tumors in adolescents and young adults. Curr Treat Options Oncol 2008; 9: 67-80.
8. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. J Am Acad Orthop Surg 2009; 17:515-27.
9. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-8. (Pubitemid 46606391)
10. Posthuma De Boer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 2011; 28:493-503.
11. Kim DH, Kim SY, Lee HJ, Song BS, Kim DH, Cho JB, et al. Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience. Cancer Res Treat 2011; 43:170-5.
12. Wuisman P, Enneking WF. Prognosis for patients who have osteosarcoma with skip metastasis. J Bone Joint Surg Am 1990; 72:60-8. (Pubitemid 20076557)
13. Xu J, Shen J, Ding Y, Shen HY, Zeng ZP, Ma RF, et al. The clinical value of combined use of MR imaging and multi-slice spiral CT in limb salvage surgery for orthopaedic oncology patients: initial experience in nine patients. Radiol Oncol 2012; 46:189-97.
14. Chen J, Zhao Y, li X, Sun P, Wang M, Wang R, et al. Imaging primary prostate cancer with llC-Choline PET-CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness. Radiol Oncol 2012; 46:179-88.
15. Kim JS, Jeong YJ, Sohn MH, Jeong HI, Lim ST, Kim DW, et al. Usefulness of F-18 FDG PET/CT in subcutaneous panniculitis-like T cell lymphoma: disease extent and treatment response evaluation. Radiol Oncol 2012; 46:279-83.
16. Lakkaraju A, Patel CN, Bradley KM, Scarsbrook AF. PET/CT in primary musculoskeletal tumours: a step forward. Eur Radiol 2010; 20:2959-72.
17. Treglia G, Cason E, Fagioli G. Recent applications of nuclear medicine in diagnostics (first part), italj Med. 2010; 4:84-91.
18. Treglia G, Salsano M, Stefanelli A, Mattoli MV, Giordano A, Bonomo L Diagnostic accuracy of UF-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. Skeletal Radiol 2012; 41: 249-56.
19. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000; 41:1695-701.
20. Kneisl JS, Patt JC, Johnson JC, Zuger JH. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin Orthop Relat Res 2006; 450:101-4. (Pubitemid 44342122)
21. Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 2009; 36:1944-51.
22. Fugle HM, Jergensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high- grade bone and soft-tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging 2012; 39:1416-24.
23. Garcia R, Kim EE, Wong FC, Korkmaz M, Wong WH, Yang DJ, et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37:1476-9. (Pubitemid 26321626)
24. Volker T, Denecke T, Steffen I, Misch D, Schonberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25:5435-41. (Pubitemid 350232220)
25. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft- tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007; 245:839-47. (Pubitemid 350127355)
26. Piperkova E, Mikhaeil M, Mousavi A, Libes R, Viejo-Rullan F, Lin H. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin Nucl Med 2009; 34:146-50.
27. London K, Stege C, Cross S, Onikul E, Graf N, Kaspers G, et al. 18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors. Pediatr Radiol 2012; 42:418-30.
28. Bandopadhyaya GP, Gupta P, Singh A, Shukla J, Rastogi S, Kumar R, et al. (99m)Tc-DMSA (V) in evaluation of osteosarcoma: comparative studies with (18JF-FDG PET/CT in detection of primary and malignant lesions. ISRN Oncol. 2012; 2012:371830.
29. Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, Bielack S, Jurgens H, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12:479-86. (Pubitemid 32472101)
30. lagaru A, Chawla S, Menendez L, Conti PS. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 2006; 27:795-802. (Pubitemid 44401248)
31. Cistaro A, Lopci E, Gastaldo L, Fania P, Brach Del Prever A, et al. The role of (18) F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. Pediatr Blood Cancer. 2012; 59:1206-10.